止嗽丸对慢性阻塞性肺疾病稳定期肺肾两虚证患者BODE指数及生活质量的影响
|
摘要
目的观察止嗽丸对慢性阻塞性肺疾病(COPD)稳定期肺肾两虚证的临床疗效。方法将符合纳入标准的患者随机分为治疗组及对照组,治疗组予止嗽丸联合舒利迭治疗,对照组予舒利迭治疗,两组治疗疗程均为6个月,观察两组患者治疗前、治疗3个月、治疗6个月BODE指数及生活质量的变化。结果两组患者治疗前BMI、FEV1%、6MWD、mMRC、BODE分值差异均无统计学意义(P均>0.05),治疗3、6个月后两组患者FEV1%、6MWD评分均高于同组治疗前(P均<0.05),mMRC、BODE分值低于同组治疗前(P均<0.05),且治疗组治疗6个月后FEV1%、6MWD、mMRC均高于对照组,BODE分值均低于对照组(P均<0.05);两组患者治疗前SGQR评分差异无统计学意义(P>0.05),两组患者治疗3、6个月后SGQR评分均低于治疗前(P均<0.05);治疗组治疗6个月评分低于对照组(P<0.05)。结论止嗽丸可改善COPD稳定期肺肾两虚证患者BODE指数,提高患者运动耐量及生活质量。
Objective To observe the clinical effect of Zhisou Pill on lung and kidney deficiency syndrome in stable stage of chronic obstructive pulmonary disease(COPD). Methods Patients who met the inclusion criteria were randomly divided into treatment group and control group. The treatment group was treated with Zhisou Pill and seretide,while the control group was treated with Seretide for 6 months. The changes of BODE index and quality of life were observed before,after and after treatment for 3 months and 6 months.Results There was no significant difference in BMI,FEV1%,6 MWD,mMRC and BODE scores between the two groups before treatment(P all >0.05). FEV1% and 6 MWD scores of the two groups after 3 and 6 months of treatment were higher than those before treatment(P all <0.05),while the scores of m MRC and BODE were lower than those before treatment(P all <0.05),and the scores of FEV1%,6 MWD and m MRC in the treatment group were higher than those in the control group and lower than those in the control group after6 months of treatment(P all <0.05). There was no significant difference in SGQR score between the two groups before treatment(P>0.05). The SGQR score of the two groups after 3 months and 6 months of treatment was lower than that before treatment(P all <0.05);the SGQR score of the treatment group was lower than that of the control group after 6 months of treatment(P<0.05). Conclusion Zhisou Pill can improve BODE index,exercise tolerance and quality of life in patients with stable COPD with deficiency of both lung and kidney.
Objective To observe the clinical effect of Zhisou Pill on lung and kidney deficiency syndrome in stable stage of chronic obstructive pulmonary disease(COPD). Methods Patients who met the inclusion criteria were randomly divided into treatment group and control group. The treatment group was treated with Zhisou Pill and seretide,while the control group was treated with Seretide for 6 months. The changes of BODE index and quality of life were observed before,after and after treatment for 3 months and 6 months.Results There was no significant difference in BMI,FEV1%,6 MWD,mMRC and BODE scores between the two groups before treatment(P all >0.05). FEV1% and 6 MWD scores of the two groups after 3 and 6 months of treatment were higher than those before treatment(P all <0.05),while the scores of m MRC and BODE were lower than those before treatment(P all <0.05),and the scores of FEV1%,6 MWD and m MRC in the treatment group were higher than those in the control group and lower than those in the control group after6 months of treatment(P all <0.05). There was no significant difference in SGQR score between the two groups before treatment(P>0.05). The SGQR score of the two groups after 3 months and 6 months of treatment was lower than that before treatment(P all <0.05);the SGQR score of the treatment group was lower than that of the control group after 6 months of treatment(P<0.05). Conclusion Zhisou Pill can improve BODE index,exercise tolerance and quality of life in patients with stable COPD with deficiency of both lung and kidney.
引文
[1]申永春,文富强. 2017年慢性阻塞性肺疾病全球创议更新解读[J].中国实用内科杂志,2017,37(2):132-135.
[2]郝正华,张虹.慢性阻塞性肺疾病中医治疗进展[J].辽宁中医杂志,2015,42(6):1376-1378.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志:电子版,2014,6(2):67-80.
[4]中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医诊疗指南(2011版)[J].中医杂志,2012,53(1):80-84.
[5] Celli BR,Cote CG,Marn JM,et al. The body mass index,air flowob-struction,dyspnea,and exercise capacity index in chronic obstructive pulmonary disease[J]. N Engl J Med,2004,350(10):1005-1012.
[6] Jones PW,Quirk FH,Baveystock CM,et al. The st george’s respiratory questionnaire[J]. Respir Med,1991,85 suppl B(suppl 2):25-31.
[7]王心悦,姚亮.培土生金法治疗慢性阻塞性肺疾病稳定期肺脾虚证的研究进展[J].现代中西医结合杂志,2018,27(30):3412-3416.
[8]张文晋,雪婷,付雪艳,等.回药治疗咳嗽方剂收集整理[J].中国中药杂志,2015,40(1):154-159.
[9]张文晋,刘悦,张新慧,等.回药治疗哮喘方剂收集整理[J].中国中药杂志,2015,40(4):753-757.
[10]尹平辉,陈欣,吴文钦,等. BODE指数评估中重度慢性阻塞性肺疾病稳定期肺康复治疗[J].临床肺科杂志,2009,14(8):1021-1022.
[2]郝正华,张虹.慢性阻塞性肺疾病中医治疗进展[J].辽宁中医杂志,2015,42(6):1376-1378.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志:电子版,2014,6(2):67-80.
[4]中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医诊疗指南(2011版)[J].中医杂志,2012,53(1):80-84.
[5] Celli BR,Cote CG,Marn JM,et al. The body mass index,air flowob-struction,dyspnea,and exercise capacity index in chronic obstructive pulmonary disease[J]. N Engl J Med,2004,350(10):1005-1012.
[6] Jones PW,Quirk FH,Baveystock CM,et al. The st george’s respiratory questionnaire[J]. Respir Med,1991,85 suppl B(suppl 2):25-31.
[7]王心悦,姚亮.培土生金法治疗慢性阻塞性肺疾病稳定期肺脾虚证的研究进展[J].现代中西医结合杂志,2018,27(30):3412-3416.
[8]张文晋,雪婷,付雪艳,等.回药治疗咳嗽方剂收集整理[J].中国中药杂志,2015,40(1):154-159.
[9]张文晋,刘悦,张新慧,等.回药治疗哮喘方剂收集整理[J].中国中药杂志,2015,40(4):753-757.
[10]尹平辉,陈欣,吴文钦,等. BODE指数评估中重度慢性阻塞性肺疾病稳定期肺康复治疗[J].临床肺科杂志,2009,14(8):1021-1022.